Apollo, Tatas partner for Covid testing

6 122
Dr. Sangita Reddy, Joint MD, Apollo Hospitals

 Rohit Shishodia
Apollo Hospitals and Tata Medical and Diagnostics (Tata MD) of Tata Group have collaborated to introduce TataMD CHECK, the world’s first CRISPR Cas-9 based diagnostic test, to help increase testing for Covid-19 across the country. TataMD CHECK is a viral detection test with high accuracy and a quick result turnaround time.

Apollo Hospitals, along with its subsidiary Apollo Diagnostics, will offer the Tata MD CHECK testing in the National Capital Region from the first week of December, 2020, and shortly thereafter, it will be rolled out across all major centres including Kolkata, Mumbai, Hyderabad, Bangalore, Chennai, Ahmedabad and Pune, followed by a second phase in other cities.

TataMD CHECK, powered by FELUDA, is the world’s first Covid diagnostic test based on the DNA genome editing tool CRISPR Cas-9. The FELUDA diagnostic technology platform has been developed by Institute of Genomics and Integrative Biology (CSIR- IGIB).

During the next few weeks, Apollo Hospitals group will ensure the availability of TataMD Check testing in eight hospitals in phase 1 and the location-wise quantities will be ramped up based on the demand and need for expanding this to other centres.

The nationwide network of Apollo Health and Lifestyle Ltd has over 100 clinics, 75 labs and over 600 collection centres in 15 states across the country. These will be progressively utilised as needed to enhance the reach and convenience to patients.

Tata MD will help train the key diagnostic clinicians and staff at Apollo Hospitals and Apollo Diagnostics on new technology and effective testing protocols in the next few weeks. With its inherent advantages, TataMD Check is expected to help deliver quicker results and higher throughput of testing volumes as there are no minimum batch sizes limitations.

Dr. Sangita Reddy, Joint MD, Apollo Hospitals (AHEL) and Managing Director, Apollo Health and Lifestyle Limited (AHLL), said, “The addition of Tata MD check as part of the testing arsenal will be a boost to the ongoing efforts that the country has been waging against this pandemic. We at Apollo are happy to partner with the Tata Group in what is potentially a revolutionary advancement in the Covid Testing Landscape.”

“To create seamless anytime anywhere access for booking, individuals can download Apollo 24/7 app with the benefit of availing reports within 2hrs,” she added.

"We believe that the association with Apollo Hospitals will catalyse the rapid adoption of TataMD CHECK as the efficient and preferred testing option as we begin to resume our lives again,” added Girish Krishnamurthy, CEO and MD, Tata Medical and Diagnostics.


  1. Be first to post your comments

Your Comment

Your email address will not be published. Required fields are marked *



Back to Top